Anti-fibrotic potential of AT2 receptor agonists

Research output: Contribution to journalReview ArticleResearchpeer-review

65 Citations (Scopus)


There are a number of therapeutic targets to treat organ fibrosis that are under investigation in preclinical models. There is increasing evidence that stimulation of the angiotensin II type 2 receptor (AT2 R) is a novel anti-fibrotic strategy and we have reviewed the published in vivo preclinical data relating to the effects of compound 21 (C21), which is the only nonpeptide AT2 R agonist that is currently available for use in chronic preclinical studies. In particular, the differential influence of AT2 R on extracellular matrix status in various preclinical fibrotic models is discussed. Collectively, these studies demonstrate that pharmacological AT2 R stimulation using C21 decreases organ fibrosis, which has been most studied in the setting of cardiovascular and renal disease. In addition, AT2 R-mediated anti-inflammatory effects may contribute to the beneficial AT2 R-mediated anti-fibrotic effects seen in preclinical models.

Original languageEnglish
Article number564
Number of pages7
JournalFrontiers in Pharmacology
Publication statusPublished - 31 Aug 2017


  • AT receptor
  • Cardiac fibrosis
  • Compound 21
  • Inflammation
  • Renal fibrosis

Cite this